PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

DFE Pharma appoints Peter Rose as new Chief Operating Officer

The appointment reinforces DFE Pharma’s commitment to reliable supply, scalable operations and continuous improvement.

DFE Pharma, a global leader in pharmaceutical excipients, has appointed Peter Rose as Chief Operating Officer, effective 1 September, when he also joined the company’s Leadership Team. He succeeds Teun Heijnen, who will retire at the end of 2026.

Peter brings more than two decades of experience in the pharmaceutical industry, following the start of his career in the dairy sector. His core expertise lies in building and developing operations teams while driving innovation at scale. Most recently, he served as Vice President and Managing Director at LGC, following a long and successful career across various areas of the pharmaceutical industry, where he held senior manufacturing and operations leadership roles and headed complex operations units and greenfield projects.

Over the course of his career, Peter has demonstrated a strong ability to turn operational challenges into practical, scalable solutions, improving efficiency, quality and delivery performance. He has also built a strong track record in developing new processes and approaches that enhance production outcomes and support long-term business growth. With a pragmatic, hands-on leadership style, he sets clear direction, encourages ownership, and creates the conditions for teams to continuously improve.

“Operational excellence is central to how we deliver on our promises to customers,” said Dr. Sven Abend, CEO of DFE Pharma. “Peter’s experience in building strong operations teams, improving performance, and driving practical innovation will help us further strengthen reliability, agility, and customer focus across our organization. His leadership approach is strongly aligned with our value of ‘Better every day’: continuously improving, taking accountability, and delivering meaningful value for customers and, ultimately, patients.”

DFE Pharma also thanks Teun Heijnen for his dedication and valuable contributions over the years. The company looks forward to celebrating his achievements closer to his retirement at the end of 2026.

About DFE Pharma

DFE Pharma is a global leader in excipient solutions. We empower pharmaceutical companies to develop and manufacture drug products with speed and confidence, by combining the purest excipients with supply security, technical expertise, and a commitment to sustainability. Our high-quality functional excipients are used in the pharmaceutical, biopharmaceutical, and nutraceutical industries for oral solid dose (OSD), respiratory and parenteral formulations.

With more than 125 years of experience and around 450 people worldwide, we serve over 5,000 customers in 100+ countries worldwide. Headquartered in Goch, Germany, DFE Pharma is committed to supporting (bio)pharmaceutical companies in improving patients’ lives, driven by our purpose: Your medicines, our solutions. Moving to a healthier world.

Learn more at www.dfepharma.com or follow us on social media.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC